Ownership history in Bridgefront Capital, LLC · 8 quarters on record
This page tracks every 13F SEC filing in which Bridgefront Capital, LLC reported a position in GLAXOSMITHKLINE PLC (GSK). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 9,531 | +319 | +3.5% | 0.12% | $411K | $42.44 |
| 2025 Q2 | REDUCED | 9,212 | -2,646 | -22.3% | 0.09% | $354K | $37.35 |
| 2025 Q1 | REDUCED | 11,858 | -4,807 | -28.8% | 0.13% | $459K | $37.25 |
| 2024 Q4 | ADDED | 16,665 | +7,037 | +73.1% | 0.19% | $564K | $32.17 |
| 2024 Q3 | ADDED | 9,628 | +3,394 | +54.4% | 0.15% | $394K | $38.44 |
| 2023 Q4 | REDUCED | 6,234 | -7,551 | -54.8% | 0.17% | $231K | $33.91 |
| 2022 Q4 | ADDED | 13,785 | +1,375 | +11.1% | 0.34% | $484K | $30.91 |
| 2021 Q2 | INITIATED | 12,410 | — | — | 0.19% | $494K | $32.70 |
As of 2025 Q4 — sorted by position size